EBR Systems Reports Q2 2026 Progress in WiSE Commercial Rollout
Key points
- 46 WiSE commercial implants completed during Q2 2026
- Signed 17 new purchasing contracts and trained 26 new physicians
- More than half of activated accounts completed three or more WiSE implants
Full summary
EBR Systems, Inc., developer of the world's only wireless cardiac pacing device for heart failure, provided a preliminary update on its commercial activity for the quarter ended 30 June 2026. The company completed 46 WiSE commercial implants during Q2 2026, bringing the total implants across the pilot phase and Limited Market Release to 117. EBR signed 17 new purchasing contracts and trained 26 new physicians during the quarter, bringing cumulative purchasing contracts signed to 52 and trained physicians to 90. Commercial execution is increasingly focused on deeper utilization within activated accounts, with more than half now having completed three or more WiSE implants. The company expects to report revenue in the range of US$2.50M to US$2.60M for Q2 2026, based on preliminary unaudited quarter-end results. EBR continues to see positive demand for WiSE, with encouraging numbers of patients being identified and scheduled for H2, 2026.
Guidance
EBR expects to report revenue in the range of US$2.50M to US$2.60M for Q2 2026
Outlook
EBR continues to see positive demand for WiSE, with encouraging numbers of patients being identified and scheduled for H2, 2026.
Summary generated by a large language model. Please interpret with care.